cholecalciferol and Syndrome

Topics: Cholecalciferol; Diagnosis, Differential; Fractures, Spontaneous; Humans; Hypophosphatemia; Osteomalacia; Phosphates; Prognosis; Rickets; Syndrome; Vitamin D Deficiency

Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Azathioprine; Chloroquine; Cholecalciferol; Chronic Disease; Erythema Nodosum; Female; Humans; Levamisole; Lung Diseases; Lung Neoplasms; Lymphoma; Penicillamine; Sarcoidosis; Syndrome; Uveitis, Anterior

Hungry Bone Syndrome (HBS) refers to rapid, profound, and prolonged hypocalcemia associated with hypophosphatemia and hypomagnesemia occurring in patients with increased bone turnover after successful management of the underlying disorder. We describe a male patient with primary hyperparathyroidism (PHPT), in whom HBS was diagnosed 6 months after parathyroidectomy. Histopathologic examination revealed an atypical parathyroid adenoma (APA), while immunohistochemistry showed cell proliferation index Ki-67 10% and overexpression of cyclin D1 (>90%). Preoperative treatment with vitamin D3 had normalized 25OHD and alkaline phosphatase levels, reflected in an improvement in bone turnover prior to surgery. Postoperative treatment for HBS with alfacalcidol, calcium, vitamin D3 and magnesium was administered for a long period. This treatment prevented severe postoperative hypocalcemia and he was discharged two days later. Preoperative cinacalcet treatment did not reduce hypercalcemia implying that the tumor had lack of calciumsensing receptors (CaSR). In conclusion, preoperative restoration of low 25OHD levels is essential for prevention of HBS. Postoperative treatment with active metabolites of vitamin D must be initiated as early as possible, in order to prevent or minimize the development of HBS, and to reduce the duration of hospitalization.

Topics: Adenoma; Adult; Bone Density Conservation Agents; Calcium; Calcium-Regulating Hormones and Agents; Cholecalciferol; Cinacalcet; Humans; Hydroxycholecalciferols; Hyperparathyroidism; Hypocalcemia; Hypophosphatemia; Magnesium; Male; Parathyroid Neoplasms; Parathyroidectomy; Postoperative Complications; Syndrome

Fragility fractures are a major burden for health and social care in elderly people. In order to identify earlier the "frail elders", new concepts of "dysmobility syndrome" and skeletal muscle function deficit (SMFD), including sarcopenia, osteoporosis, obesity, and mobility limitation, leading to a higher risk of fractures, have been recently introduced. There are very few studies investigating the association between fragility fractures and both the dysmobility syndrome and the SMFD.. The objective of our study is to investigate the role of previous fragility fractures as a risk factor in determining the dysmobility syndrome and/or the SMFD in post-menopausal women.. In this case-control study, we retrospectively examined data from the medical records of post-menopausal women aged 50 or older. We divided the study population in two groups. The first group includes women with a previous fragility fracture (cases) and the other group includes women without any previous osteoporotic fracture (controls). We identified the subjects with "dysmobility syndrome", "dynapenic SMFD", "sarcopenic SMFD", and "mixed SMFD" in both groups. Data collected refer to a 6-month period.. We retrieved data of 121 post-menopausal women, 77 (63.64%) had already sustained a fragility fracture at any site (cases). The risk for dysmobility syndrome was significantly higher (adjusted OR for age and serum 25-OH vitamin D3 of 2.46) in the cases compared with the controls.. An early diagnosis of conditions limiting mobility, including dysmobility syndrome, might be useful to identify, among patients with osteoporotic fractures, those who might have a higher risk of a new fragility fracture.

Topics: Aged; Aged, 80 and over; Bone Density; Case-Control Studies; Cholecalciferol; Female; Frail Elderly; Humans; Italy; Mobility Limitation; Muscle Weakness; Muscle, Skeletal; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prevalence; Risk Assessment; Risk Factors; Sarcopenia; Syndrome

Topics: Basal Ganglia Diseases; Calcinosis; Calcium; Cholecalciferol; Drug Therapy, Combination; Humans; Hypoparathyroidism; Male; Middle Aged; Syndrome

Topics: Cholecalciferol; Drug Hypersensitivity; Female; Humans; Hypercalcemia; Infant; Male; Syndrome

Topics: Adult; Brain Diseases, Metabolic; Calcinosis; Cholecalciferol; Female; Humans; Hypoparathyroidism; Syndrome; Vitamin D Deficiency

We report a rare case of Albright's syndrome associated with both a soft-tissue myxoma and hypophosphataemic osteomalacia. Renal tubular function was preserved, except for glycosuria. Serum levels of 1,25(OH)2 vitamin D3 were normal. Excision of the myxoma did not influence the biochemical abnormalities, nor did standard doses of vitamin D3 or 1 alpha-OH vitamin D3. The previously reported cases of hypophosphataemic osteomalacia associated with fibrous dysplasia and mesenchymal tumours are reviewed and the underlying mechanism discussed.

Topics: Cholecalciferol; Female; Fibrous Dysplasia of Bone; Humans; Hydroxycholecalciferols; Hypophosphatemia, Familial; Middle Aged; Myxoma; Osteomalacia; Soft Tissue Neoplasms; Syndrome

Cutaneous 7-dehydrocholesterol, exposed to ultraviolet radiation, converts to previtamin D3, which in turn converts in skin to vitamin D3 and is carried into the circulation. We investigated the feasibility of the photochemical conversion in skin of hydroxylated derivatives of 7-dehydrocholesterol - such as 1 alpha, 25-dihydroxy-7-dehydrocholesterol (1 alpha, 25-(OH)2-7-DHC) - to the corresponding hydroxylated previtamin as an alternative method of delivery of 1 alpha, 25-dihydroxyvitamin D3 (1 alpha, 25-(OH)2-D3) to subjects who are deficient in the endogenous metabolite. In human volunteers and in vitamin-D-deficient rats [24-3H] 1 alpha, 25-(OH)2-D3 appeared in blood after [24-3H] 1 alpha, 25-(OH)2-7-DHC was applied to the skin and exposed to ultraviolet radiation. In anephric rats, intestinal calcium absorption and serum calcium levels were elevated after a topical dose of 1 alpha, 25-(OH)2-7-DHC combined with ultraviolet phototherapy. Delivery of equivalent doses of 1 alpha, 25-(OH)2-D3 through the skin and orally showed that there was more prolonged stimulation in intestinal calcium absorption and serum calcium elevation after cutaneous administration. The photochemical conversion of precursors may be useful in the treatment of patients with impaired vitamin-D metabolism.

Topics: Administration, Topical; Adult; Animals; Calcitriol; Calcium; Cholecalciferol; Cholesterol; Dihydroxycholecalciferols; Female; Humans; Hydroxycholecalciferols; Intestinal Mucosa; Male; Photochemistry; Rats; Skin; Skin Temperature; Syndrome; Ultraviolet Rays; Ultraviolet Therapy; Vitamin D; Vitamin D Deficiency

Topics: Cholecalciferol; Dermatitis, Exfoliative; Keratosis; Syndrome